Epstein Secrets

roff Subject: Fwd: FOURIER: Significant LDL Reduction with Evolocumab Date: Fri, 24 Mar 2017 11:17:36 +0000 Lesley please forward to Jeffrey rs Rony Shimony, M.D. F.A.C.C. Associate Professor of Medicine, Cardiology Icahn School of Medicine at Mount Sinai Director, Clinical Cardiology Mount Sinai West

pproximately 50% higher than had been postulated led to a shorter required duration of follow-up to accrue the prespecified number of events." Dr. Sabatine emphasized the importance of aggressive LDL-lowering treatment in the future. "We need to treat LDL cholesterol more aggressively, and now we have a

FOURIER: Significant LDL Reduction with Evolocumab Date: March 24, 2017 at 7:17:36 AM EDT To: Lesley Groff < Lesley please forward to Jeffrey rs Rony Shimony, M.D. F.A.C.C. Associate Professor of Medicine, Cardiology Icahn School of Medicine at Mount Sinai Director, Clinical Cardiology Mount Sinai West

pproximately 50% higher than had been postulated led to a shorter required duration of follow-up to accrue the prespecified number of events." Dr. Sabatine emphasized the importance of aggressive LDL-lowering treatment in the future. "We need to treat LDL cholesterol more aggressively, and now we have a

duction with Evolocumab Date: Fri, 24 Mar 2017 11:18:21 +0000 will do..thanks! On Mar 24, 2017, at 7:17 AM, Lesley please forward to Jeffrey rs Rony Shimony, M.D. F.A.C.C. Associate Professor of Medicine, Cardiology Icahn School of Medicine at Mount Sinai Director, Clinical Cardiology Mount Sinai West

approximately 50% higher than had been postulated led to a shorter required duration of follow-up to accrue the prespecified number of events' Dr. Sabatine emphasized the importance of aggressive LDL-lowering treatment in the future. "We need to treat LDL cholesterol more aggressively, and now we have a